BIOFRONTERA INC (BFRI) Stock Price, Quote, News and Overview
NASDAQ:BFRI - Nasdaq - US09077D2099 - Common Stock - Currency: USD
BFRI Quote, Performance and Key Statistics
1.11
-0.04 (-3.48%)
The current stock price of BFRI is 1.11 USD. In the past month the price increased by 2.78%. In the past year, price increased by 20.65%.
BFRI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About BFRI
Company Profile
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. The company is headquartered in Woburn, Massachusetts and currently employs 85 full-time employees. The company went IPO on 2021-10-14. The firm is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The firm's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
Company Info
BIOFRONTERA INC
120 Presidential Way,, Suite 330
Woburn MASSACHUSETTS US
CEO: Erica Monaco
Employees: 84
Company Website: https://www.biofrontera-us.com/
Investor Relations: https://www.biofrontera.com/en/investors
Phone: 17812451325
BIOFRONTERA INC / BFRI FAQ
What is the stock price of BIOFRONTERA INC today?
The current stock price of BFRI is 1.11 USD. The price decreased by -3.48% in the last trading session.
What is the ticker symbol for BIOFRONTERA INC stock?
The exchange symbol of BIOFRONTERA INC is BFRI and it is listed on the Nasdaq exchange.
On which exchange is BFRI stock listed?
BFRI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIOFRONTERA INC stock?
8 analysts have analysed BFRI and the average price target is 11.73 USD. This implies a price increase of 956.76% is expected in the next year compared to the current price of 1.11. Check the BIOFRONTERA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIOFRONTERA INC worth?
BIOFRONTERA INC (BFRI) has a market capitalization of 8.60M USD. This makes BFRI a Nano Cap stock.
How many employees does BIOFRONTERA INC have?
BIOFRONTERA INC (BFRI) currently has 84 employees.
What are the support and resistance levels for BIOFRONTERA INC (BFRI) stock?
BIOFRONTERA INC (BFRI) has a support level at 1.09 and a resistance level at 1.17. Check the full technical report for a detailed analysis of BFRI support and resistance levels.
Is BIOFRONTERA INC (BFRI) expected to grow?
The Revenue of BIOFRONTERA INC (BFRI) is expected to grow by 12.29% in the next year. Check the estimates tab for more information on the BFRI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIOFRONTERA INC (BFRI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BFRI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BFRI, evaluating the profitability, health, valuation and growth aspects
- BIOFRONTERA INC (BFRI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIOFRONTERA INC (BFRI) Sales and EPS estimates to see what analysts future expectations are.
- BIOFRONTERA INC (BFRI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIOFRONTERA INC (BFRI) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIOFRONTERA INC (BFRI) Stock Chart to make your own analysis
- BIOFRONTERA INC (BFRI) Latest news and press-releases to stay up to date.
Does BIOFRONTERA INC (BFRI) stock pay dividends?
BFRI does not pay a dividend.
When does BIOFRONTERA INC (BFRI) report earnings?
BIOFRONTERA INC (BFRI) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of BIOFRONTERA INC (BFRI)?
BIOFRONTERA INC (BFRI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.71).
What is the Short Interest ratio of BIOFRONTERA INC (BFRI) stock?
The outstanding short interest for BIOFRONTERA INC (BFRI) is 4.24% of its float. Check the ownership tab for more information on the BFRI short interest.
BFRI Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to BFRI. When comparing the yearly performance of all stocks, BFRI is one of the better performing stocks in the market, outperforming 87.9% of all stocks.
BFRI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to BFRI. While BFRI seems to be doing ok healthwise, there are quite some concerns on its profitability.
BFRI Financial Highlights
Over the last trailing twelve months BFRI reported a non-GAAP Earnings per Share(EPS) of -5.71. The EPS increased by 71.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.33% | ||
| ROE | -232.13% | ||
| Debt/Equity | 0 |
BFRI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to BFRI. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 83.94% and a revenue growth 12.29% for BFRI